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IMMUNOTHERAPY AND TRANSPLANTATION FOR MULTIPLE MY-
ELOMA: EARLY RECOVERY OF AGGRESSIVE CYTOTOXIC CELLS AND
IMPROVED IMMUNE RECOVERY
Bengtson, E.M.1, Wu, J.-Y.2, Fitzmaurice, T.F.1, Cornell, C.J.1,
Ely, P.1, Gautier, M.1, Lowrey, C.H.1, Meehan, K.R.1 1Dartmouth-
Hitchcock Medical Center, Lebanon, NH; 2Dartmouth Medical School,
Hanover, NH.
Autologous peripheral blood stem cell transplantation (APB-
SCT) is effective for the treatment of multiple myeloma (MM);
however, the majority of patients relapse. Recent evidence shows
an improved outcome if absolute lymphocyte count is increased
immediately following APBSCT in patients with a hematologic
malignancy. We designed a phase II trial evaluating a dose escala-
tion of SQ IL-2 and standard-dose GM-CSF posttransplantation
for myeloma patients. Patients (n  18) received melphalan 200
mg/m2 with GM-CSF 250 mg/m2/day beginning on day 5. IL-2
began on day 0 and continued for 5 days per week for 4 weeks.
Peripheral blood samples were obtained at baseline (pretransplan-
tation) and every week for 4 weeks posttransplantation and evalu-
ated using ﬂow cytometry for cell subsets with antibodies directed
against CD3, CD4, CD8, CD25, and CD56. Control patients (n
11) consisted of MM patients who received melphalan 200 mg/m2
with either G or GM-CSF without IL-2. IL-2 at a dose of 1  106
U/m2/day was not tolerated in 2 of 6 patients due to grade 4 fatigue
and diarrhea (n  1) and grade 4 SVT (n  1). A dose of 6  105
U/m2/day was well tolerated by 12 patients. At this dose, level 3 or
greater toxicities included nausea (n  5), diarrhea (n  3), an-
orexia (n  11), and mucositis (n  9). Engraftment of neutrophils
occurred on day 12 (median; range, 11–17 days) and platelets on
day 14 (median; range, 9–74 days). Only 3 of 18 patients have
relapsed/progressed, with a median follow-up of 16.4 months.
Absolute lymphocyte counts on days 10–15 were increased by
152% in the IL-2 cohort (mean; range, 25%-390%) compared
with the control group. At day 21, there was a marked increase in
the number of CD8 CTLs (43%  7.5%), CD56 NK cells
(78.3%  9.1%), and CD8CD56 NKT cells (36.8%  9.8%)
compared with baseline levels. Cytotoxicity of day 21 PBMNCs in
the IL-2 cohort was strikingly increased at 28.1%, compared with
5.5% at baseline when tested against a human myeloma cell line
(RPMI 8226) using chromium release assays (E:T ratio  100:1).
These results demonstrate a very-well-tolerated regimen of immedi-
ate posttransplantation immunotherapy with marked increase in the
number and function of early cytotoxic effector cells. The enhanced
immune recovery may translate into an improved outcome.
PEDIATRIC DISORDERS
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TOTAL BODY IRRADIATION DOSE AND PULMONARY TOXICITY IN
PEDIATRIC PATIENTS
Kornguth, D.G., Mahajan, A., Ka Wah, C., Antolak, J., Sanders, K.E.,
Borghero, Y., Chul, H.S. University of Texas M.D. Anderson Cancer
Center, Houston, TX.
Background: The optimal dose for pediatric total body irradia-
tion (TBI) before bone marrow transplantation (BMT) is contro-
versial. Higher doses contribute to normal tissue toxicity, whereas
lower doses decrease efﬁcacy of the treatment. We compared
overall survival (OS), freedom from relapse (FFR), and freedom
from life-threatening pulmonary events (FPE) in 2 TBI regimens
that have been used on protocols at our institution. Methods:
Between April 1993 and March 2003, 61 pediatric patients with
hematologic disorders were treated on chemoradiotherapy proto-
cols before receiving BMT. Two TBI fractionation schedules were
used for these patients. Twenty-nine patients received 12 Gy in 4
fractions, with all but 1 patient receiving cyclophosphamide-based
chemotherapy. The remaining 32 patients received 9 Gy in 3
fractions in conjunction with ﬂudarabine-based chemotherapy.
The ﬂudarabine regimen began accruing patients in 1998; the
lower radiation dose was used because of possible potentiation of
TBI-related pulmonary toxicity with ﬂudarabine. The mean fol-
low-up was 24 months for the 12-Gy group and 13 months for the
9-Gy group. Patients with acute lymphocytic leukemia, chronic
myelogenous leukemia, or acute myelogenous leukemia composed
83% of the 12- Gy group and 81% of the 9-Gy group. Retrospec-
tive review of medical records was performed to grade pulmonary
toxicity. Acute and late pulmonary toxicities that were Radiation
Therapy Oncology Group grade 4 or 5 were coded as pulmonary
events. OS, FFR, and FPE were computed using the method of
Kaplan and Meier. Results: The 2 regimens did not differ statis-
tically with respect to OS, FFR, FPE or engraftment rate. Actu-
rarial 2-year statistics for the 12-Gy and 9-Gy regimens were as
follows: OS, 28% and 40% (P  .25); FFR, 51% and 58% (P 
.30); FPE, 55% and 62% (P  .81). The engraftment rates were
90% for the 12-Gy group and 92% for the 9-Gy group (P  .89).
Conclusions: The transplantation preparative regimen of 9 Gy
TBI with ﬂudarabine is at least as effective as that of 12 Gy TBI
with cyclophosphamide in terms of FFR and engraftment rate
without a signiﬁcant increase in pulmonary toxicity.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION IS EFFECTIVE CURA-
TIVE TREATMENT IN PEDIATRIC REFRACTORY/AGGRESSIVE LANGER-
HANS CELL HISTIOCYTOSIS
Caniglia, M.1, Pinto, R.M.1, Rana, I.1, Zinno, F.1, Peluso, G.1,
Lombardi, A.1, Angioni, A.1, Isacchi, G.1, Arcese, W.2, De Rossi, G.1
1Hemathology Unit, “Bambino Gesu`” Children’s Hospital, Roma, Italy;
2Hemathology Tor Vergata University, Roma, Italy.
Although the new strategies for the management of LCH have
been made considerable advances in the outcomes of pediatric
patients, the best therapeutic approach for aggressive/refractory
multisystem LCH patients remains controversial. Antiproliferative
and immunosuppressive therapy in combination with HSCT has
been proposed as the appropriate treatment for these patients with
poor prognosis. Because of the appreciable morbidity and mortal-
ity of allogeneic HSCT, this strategy has heretofore been reserved
for the few LCH patients with a very poor prognosis. In this report
we describe 4 children, age 14 months (patient 1), 27 months
(patient 2), 96 months (patient 3), and 48 months (patient 4), with
refractory aggressive MS-LCH who were treated with allogeneic
HSCT in our institution between 2001 and 2003. Disease activity
score, as well as Karnofsky status, were retrospectively calculated
for all patients at diagnosis and before HSCT. All patients pre-
sented with MSD progression despite chemotherapy with single or
multiple agents or immunosuppressive therapy. Allogeneic HSCT
was performed 10, 22, 72, and 47 months, respectively, from onset.
Patients 1 and 3 received umbilical cord blood transplantation
(UCBT) from HLA 4/6 and 5/6 mismatched unrelated donors.
Patients 2 and 4 received bone marrow transplantation (BMT)
from related HLA-identical donors. A conditioning regimen in-
cluding busulfan 4 mg/kg and ﬂudarabin 30 mg/m2 from day7 to
day 4 and thiotepa 10 mg/kg on day 3 was used as preparative
regimen. All patients received horse ATG 15 mg/kg from day 6
to day 2, cyclosporine A 3 mg/kg from day 1 to day 180, and
PDN 1 mg/kg until day 30. After HSCT, all patients are alive
with a median follow-up of 30 months (51, 39, 19, and 11 months,
respectively). The conditioning regimen was well tolerated without
major complications. Donor engraftment was demostrated in all 4
patients by PCR DNA analysis, and progressive improvement of
disease symptoms were observed after 18, 6, 8,and 6 months,
respectively. Patients 1 and 2 are disease-free, patient 3 presented
with grade III aGVHD and reduction of esophthalmous and skin
lesions, bone lesions are stable as well as for patient 4. Disease
progression was not evident in any of the patients during long-term
follow-up. We conclude that HSCT is a good curative treatment
for these patients with poor prognosis. Progressive clinical im-
provements were evident for a long time after HSCT. Selection of
patients based on early response to conventional chemotherapy
and timing of HSCT remains controversial.
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